This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Evolving Landscape of Treatment for Hepatocellular Carcinoma with Multi-Targeted Tyrosine Kinase Inhibitors and Immunotherapy

Evolving Landscape of Treatment for Hepatocellular Carcinoma with Multi-Targeted Tyrosine Kinase Inhibitors and Immunotherapy

Format

Webcast

Time to Complete

1 hour

Released

June 24, 2019

Expires

June 24, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM
1.00 / CE for Nurses

Accredited Provider

Jointly provided by Amedco and CancerNet, LLC

Commercial Supporter

Supported by Merck Sharpe & Dohme Corp., and Eisai, Inc

Program Description

This webcast is intended to improve care of patients with hepatocellular carcinoma (HCC) by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

This webcast is designed to meet the educational needs of hematologists/oncologists, hepatologists, interventional radiologist, gastroenterologists, transplant surgeons, pathologists and other health care professionals who diagnose, treat, and manage patients with HCC.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Identify and select multitargeted kinase inhibitors in the treatment of unresectable hepatocellular carcinoma (HCC)
  • Assess the efficacy and safety of immune checkpoint inhibitors in the treatment of HCC

Conflict Of Interest Disclosure Policy

It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Faculty

Ghassan Abou-Alfa, MD, MBA
Attending
Memorial Sloan Kettering Cancer Center
Professor
Weill Medical College at Cornell University
New York, NY

Dr. Abou-Alfa discloses the following:
Consultant: 3DMedcare, Agios, AlignMed, Amgen, Antengene, Aptus, ASLAN, Astellas, AstraZeneca, Bayer, BeiGene, Bioline, BMS, Boston Scientifc, Bridgebio, CARsgen, CASI, Celgene, Cipla, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Genoscience, Halozyme, Hengrui, Incyte, Inovio, Ipsen, Jazz, Janssen, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, Novella, Onxeo, PCI Biotech, Pfizer, Pieris, QED, RedHill, Sanofi, Servier, Silenseed, SillaJen, Sobi, Targovax, Tekmira, twoXAR, Vicus, Yakult, Yiviva
Received Research Funding: ActaBiologica, Agios, Array, AstraZeneca, Bayer, BeiGene, BMS, CASI, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, MabVax, Novartis, OncoQuest, Polaris Puma, QED, Roche

Anthony El-Khoueiry, MD
Associate Professor of Medicine
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Dr. El-Khoueiry discloses the following:
Consultant/Advisory Board: Agenus, Astex, AstraZeneca, Bayer, BMS, CytomX, Eisai Inc., EMD Serono, Merck, Pieris

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE webcast:

Kamatham A. Naidu, PhD (CancerNet, LLC), has no relevant financial relationships to disclose.
Brian Waggoner (CancerNet, LLC), has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco), has no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Amedco LLC designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CE for Nurses

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Amedco LLC designates this enduring activity for a maximum of 1.00 contact hour for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Non-Endorsement of Products

Amedco does not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Instructions

There are no fees for participating and receiving CME credit for this webcast. During the period June 24, 2019 through June 24, 2020, participants must read all the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 80% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CME/CE Provider at certificate@amedcoemail.com.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

Amedco observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue